Literature DB >> 19944565

Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice.

Marie-Laure Santiago-Raber1, Isabelle Dunand-Sauthier, Tianfu Wu, Quan-Zhen Li, Satoshi Uematsu, Shizuo Akira, Walter Reith, Chandra Mohan, Brian L Kotzin, Shozo Izui.   

Abstract

Accumulating evidence supports the idea that TLR7 and TLR9 play pathogenic and protective roles, respectively, in the development of murine systemic lupus erythematosus (SLE). However, the molecular mechanism responsible for the accelerated development of SLE resulting from the deletion of TLR9 and the respective contributions of TLR7 and TLR9 to the development of different autoimmune responses against nuclear and non-nuclear autoantigens implicated in lupus nephritis have not been well defined. In the present study, we addressed these questions by assessing the effect of the TLR9 and/or TLR7 deletion on the production of various autoantibodies and the development of lupus nephritis in C57BL/6 mice congenic for the Nba2 (NZB autoimmunity 2) locus (B6.Nba2). TLR9-deficient B6.Nba2 mice displayed increased production of autoantibodies against nuclear antigens, serum retroviral gp70 and glomerular matrix antigens, and developed a markedly accelerated form of lupus nephritis. Enhanced disease was associated with functionally upregulated expression of TLR7, as documented by an increased TLR7-dependent activation of B cells and plasmacytoid dendritic cells. Notably, disease exacerbation in TLR9-deficient mice was completely suppressed by the deletion of TLR7. Our results indicate that TLR7 has a pivotal role in a wide variety of autoimmune responses against DNA- and RNA-containing nuclear antigens, retroviral gp70 and glomerular matrix antigens implicated in murine SLE, and that enhanced TLR7 activity is critical for the accelerated development of SLE in TLR9-deficient lupus-prone mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944565     DOI: 10.1016/j.jaut.2009.11.001

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  100 in total

1.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 2.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 3.  The therapeutic potential of epigenetics in autoimmune diseases.

Authors:  Maria De Santis; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

Review 4.  Historical overview of immunological tolerance.

Authors:  Ronald H Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

Review 5.  Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis.

Authors:  QiQuan Huang; Richard M Pope
Journal:  J Leukoc Biol       Date:  2010-05-19       Impact factor: 4.962

Review 6.  Nonclassical patrolling monocyte function in the vasculature.

Authors:  Graham Thomas; Robert Tacke; Catherine C Hedrick; Richard N Hanna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-02       Impact factor: 8.311

7.  TLR9 Deficiency Leads to Accelerated Renal Disease and Myeloid Lineage Abnormalities in Pristane-Induced Murine Lupus.

Authors:  Lukas Bossaller; Anette Christ; Karin Pelka; Kerstin Nündel; Ping-I Chiang; Catherine Pang; Neha Mishra; Patricia Busto; Ramon G Bonegio; Reinhold Ernst Schmidt; Eicke Latz; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2016-06-27       Impact factor: 5.422

8.  Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation.

Authors:  Purvi Mande; Bahar Zirak; Wei-Che Ko; Keyon Taravati; Karen L Bride; Tia Y Brodeur; April Deng; Karen Dresser; Zhaozhao Jiang; Rachel Ettinger; Katherine A Fitzgerald; Michael D Rosenblum; John E Harris; Ann Marshak-Rothstein
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

9.  Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.

Authors:  Nikunj M Shukla; Subbalakshmi S Malladi; Victor Day; Sunil A David
Journal:  Bioorg Med Chem       Date:  2011-05-01       Impact factor: 3.641

10.  Role of nucleic acid-sensing TLRs in diverse autoantibody specificities and anti-nuclear antibody-producing B cells.

Authors:  Yi Ting Koh; John C Scatizzi; Jennifer D Gahan; Brian R Lawson; Roberto Baccala; K Michael Pollard; Bruce A Beutler; Argyrios N Theofilopoulos; Dwight H Kono
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.